# Hiwemed

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hiwemed

- Industry: Medical Devices & Equipment
- Headquarters: Suzhou, China
- Website: www.hiwemed.com
- Latest round: Series B (Jan 17, 2025)
- Investors on record: 5

## About

Based in Suzhou, China, and established in 2021, Hiwemed is a medical device company that focuses on the R&D of blood interventional embolization products. It cooperated with medical institutions such as Sun Yat-sen University Cancer Hospital, Shandong Province Tumor Hospital, and Wuhan Union Medical College Hospital. The company has 11 invention patents. The company's self-developed HiFlamingo® balloon occlusion catheter obtained marketing authorization from NMPA in April 2024. In January 2025, it closed a series B funding.

The company provides blood vessel interventional embolization products based on biomaterials research and development. It has planned 10 types of class III medical device products. Products within include microcatheter, hydrogel microspheres, slow-release microspheres, drug-carrying embolic microspheres, and medical microspheres. The microspheres can piggyback chemotherapy drugs that enable chemotherapy drugs to work inside the tumor, as well as embolize tumor vessels. Products can be used in vascular intervention, luminal intervention, tissue intervention, and tumor intervention.

Hiwemed generates revenue by providing vascular intervention products and related services to hospitals and medical institutions.

The company will use the series B funding for product commercialization, clinical trials and research and development of new generation medical microsphere products.

## Funding rounds

- Series B, Jan 17, 2025 — Addor Capital, Wuzhong Financial Holdings Capital
- Series A, Nov 28, 2023 — Nanjing Venture Capital, Jolmo Capital, Jinkong Qiyuan Capital

## Investors

- Nanjing Venture Capital (https://capitalatlas.ai/funds/nanjing-venture-capital) — Series A
- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A
- Jinkong Qiyuan Capital (https://capitalatlas.ai/funds/jinkong-qiyuan-capital) — Series A
- Addor Capital (https://capitalatlas.ai/funds/addor-capital) — Series B
- Wuzhong Financial Holdings Capital (https://capitalatlas.ai/funds/wuzhong-financial-holdings-capital) — Series B